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Abstract
Introduction Cow’s milk allergy (CMA) is thought to affect
2–3% of infants. The signs and symptoms are nonspecific
and may be difficult to objectify, and as the diagnosis requires
cow’s milk elimination followed by challenge, often, children
are considered cow’s milk allergic without proven diagnosis.
Diagnosis Because of the consequences, a correct diagnosis
of CMA is pivotal. Open challenges tend to overestimate the
number of children with CMA. The only reliable way to
diagnose CMA is by double-blind, placebo-controlled
challenge (DBPCFC).
Therapy At present, the only proven treatment consists of
elimination of cow’s milk protein from the child’sd i e ta n d
the introduction of formulas based on extensively hydrolysed
whey protein or casein; amino acid-based formula is rarely
indicated. The majority of children will regain tolerance to
cow’s milk within the first 5 years of life.
Conclusions Open challenges can be used to reject CMA,
but for adequate diagnosis, DBPCFC is mandatory. In most
children, CMA can be adequately treated with extensively
hydrolysed whey protein or casein formulas.
Keywords Cow’smilkallergy.Double-blind
placebo-controlledfoodchallenge.DBPCFC.
Hypoallergenicformula
Introduction
T h ep r e v a l e n c eo fc o w ’s milk allergy (CMA) is
estimated to be between 2% and 3% in infants and
marginally lower in older children [1, 2]. The percentage
of parents that believe their child has CMA (or any other
food allergy), however, amounts to between 5% and 20%
[2–4]. Signs and symptoms of CMA are nonspecific and
often difficult to objectify. Due to diagnostic burdens, the
number of children treated for CMA is probably two to
three times higher than justified [5]. A wrong diagnosis of
CMA may not only result in somatisation but also in
insufficient topical treatment of eczema, fear for or
problems with the introduction of solids, and dietary
deficiencies. Moreover, the long-term elimination of cow’s
milk protein (CMP) in a sensitised child without CMA
may elicit severe adverse reactions when cow’sm i l ki s
reintroduced [6]. Careful diagnosis of CMA, therefore, is
of utmost importance.
Definitions
Adverse reactions to CMP can be present from birth, even
in exclusively breast-fed infants. Not all reactions are of
allergic nature. In 2001, the EAACI published a report on
the terminology of adverse reactions [7]. The umbrella
phrase, food hypersensitivity, covers non-allergic food
hypersensitivity (traditionally named ‘food intolerance’)
and allergic food hypersensitivity (food allergy). The latter
requires an underlying immune mechanism. Most children
with CMA have immunoglobulin E (IgE)-mediated allergy
as a manifestation of their atopic constitution, with or
without atopic eczema, asthma, or allergic rhinitis. A small
group have cell-mediated allergy with gastro-intestinal
symptoms [8].
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Although signs and symptoms themselves (Table 1) cannot
be used to diagnose CMA, history may be helpful as it can
give clues to other diagnoses. Symptoms may start after the
substitution of breast-feeding with formula feeding. The
repeated occurrence of urticaria or rash shortly after CMP
ingestion is suggestive of CMA. In general, signs and
symptoms occurring late (>2 h) after the consumption of
CMP are not caused by CMA [9]. Also, inconsistent signs
and symptoms and those that do not emerge after every
feeding must have a different aetiology.
The concurrent presence of other signs of atopy, such as
eczema, wheezing, and asthma, increases the likelihood of
CMA but cannot be used as a diagnostic proof. Especially
the relation between CMA and eczema is difficult to assess.
Although they can be present simultaneously and although
CMP challenge may aggravate moderate to severe eczema in
about 30% of cases [10–12], there is no proven relationship
with mild eczema; moreover, there is no solid evidence that
eczema can be expected to improve significantly on a CMP
elimination diet [13]. Atopic eczema should be treated
adequately with topical medication before CMA is consid-
ered [12]. Generally, other physical signs are lacking or
nonspecific. Growth should be monitored closely.
Laboratory investigation
The role of laboratory tests in CMA diagnosis is
debatable. The tests used in clinical practice only reveal
sensitisation to CMP, which is not necessarily followed by
clinically relevant allergy. Over 50% of sensitised children
do not have food allergy [14–16]. In our experience,
positive skin prick tests and allergen-specific IgE tests tend
to be falsely interpreted as proof of CMA. This is not at all
innocuous [6].
Although there is a strong positive correlation between
the level of allergen-specific IgE and the chance of having
CMA, unequivocally high specific IgE titres are rare and
may occur in non-allergic children [17–19]. In general
practice, therefore, laboratory tests are seldom helpful. The
only way to prove CMA is through elimination and
challenge.
Cow’s milk challenge
After the elimination of CMP from the child’s or the
mother’s diet, signs and symptoms should disappear within
a few days. Atopic eczema, when caused by CMA, may
take 4 weeks to improve sufficiently. Upon challenge,
renewed confrontation with CMP results in recurrence of
the presenting signs and symptoms.
Challenges may be performed either open or double-
blindly. With open challenges, both the staff performing
the test and the parents know that the child is given
CMP and in what amount. Double-blind placebo-
controlled food challenges (DBPCFC) are designed to
withhold this information both to the parents and the
staff until afterwards. They are performed with placebo
and verum in random order. CMP is concealed in a way
that both test feedings look and taste similarly.
DBPCFCs are superior to open challenges, but they are
difficult to perform, require extensive preparation and are
relatively expensive [9].
Open challenge
Open challenges can be used as the first diagnostic step.
Challenges should follow an approved protocol, suited
for the circumstances. In 1995, a national protocol for
CMA diagnosis and treatment was introduced in Dutch
well-baby clinics, including a simple open challenge,
which is still in use [20]. After 2 weeks of elimination
diet, the child ingests 10 ml of original formula while
being supervised for 1 h; on the three following days, the
formula is given in increasing amounts [20]. While
originally, the protocol was developed to avoid inappro-
priate CMA diagnoses, presently, it is thought that it
contrarily may induce falsely positive results and should
Table 1 Signs and symptoms of CMA (those printed in italics are
suggestive of severe allergy)
Gastrointestinal Vomiting, regurgitation
Abdominal pain
Colic
Diarrhoea
Constipation
Haemochezia
Skin Rash
Atopic eczema
Urticaria
Swollen lips
Angio-oedema
Pruritus
Respiratory Rhinitis
Conjunctivitis
Hoarseness, dysphagia
Wheezing, asthma
General Food refusal
Growth retardation
Iron-deficient anaemia
Irritability, disturbed sleep
Apnoea, apparent life-threatening events
Anaphylaxis
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symptom appreciation and random symptom fluctuation
increase the risk of falsely positive results. Between 27%
and 70% of open-challenge CMA diagnoses are rejected
after DBPCFC [21, 22].
Apart from this, a generally accepted open challenge
procedure has only been published in 2007, when a
European working group formulated a protocol for CMA
diagnosis in general practice meant for children with
relatively mild signs and symptoms [23]. The child’s own
formula is given in increasing amounts over 3 h (Table 2).
In our opinion, however, open challenges should only be
used to reject CMA [1, 10, 12].
DBPCFC
Double-blind challenges are the gold standard. In 2007 as
well, the Health Council of the Netherlands issued a report
asking for the general introduction of DBPCFCs [1]. Dutch
paediatric allergy centres and many hospitals already
practice DBPCFCs [24–26]. They can be performed in
well-baby clinics and general practices as well, as long as
basic precautions have been met, including thorough
knowledge of the procedure, careful patient selection and
the equipment to block adverse reactions. The importance
of DBPCFCs is underscored by the fact that between 13%
and 30% of placebo tests are eliciting adverse reactions [24,
27]. There is no generally accepted protocol for DBPCFC.
The protocol presented here is used in the Wilhelmina
Children’s Hospital [25].
Preparation The diet should be CMP free for at least
2 weeks. The patient’s condition should be stable,
especially concerning skin symptoms. Topical cortico-
steroids may be continued, but antihistamines should be
discontinued at least one week in advance. Preparation
includes a thorough history for previous adverse reactions.
Safety Tests should be performed in a day-care setting or
during admission. Depending on the severity of previous
signs and symptoms, a monitoring device and intravenous
access may be needed. Clemastine and epinephrin for
parenteral use must be at hand. The personnel should be
well trained, also regarding the management of (rare) severe
acute reactions.
Test material The child is given his/her own hypoallergenic
formula or expressed breast milk. The research kitchen
prepares coded bottles with (verum) or without (placebo)
5 g Protifar® powder (Nutricia/SHS), containing 4.4 g
CMP, per 250 ml formula.
Procedure Placebo and verum are administered on separate
days, preferably 1 week apart. The test formula is given in
increasing dosages at fixed intervals (Table 2)[ 26].
Adverse reactions are recorded. After a negative test, the
child remains under supervision for 2 h, after a positive test
for 4 h. The parents are asked to report late reactions. After
the second test, a follow-up period of at least 48 h is
observed before the seal is broken [26].
Evaluation The test is discontinued when the child
experiences objective adverse reactions, subjective reactions
that persist for 30 min or longer or repeated short-lived
subjective reactions [9]. Allergic and non-allergic reactions
are assessed separately and in the light of the child’sh i s t o r y
(Fig. 1). The final interpretation of the tests is given in
Table 3. The DBPCFC is considered negative when verum
did not elicit adverse reactions or when reactions following
verum are not worse than following placebo. Even
Table 2 CMP administration schedules during challenge
Step Open challenge; child’s own formula (Ref 34) DBPCFC; hypoallergenic formula, with 5g of Protifar® (Ref 28)
T (min) Dose (ml) CMP (mg)
a T (min) Dose (ml) CMP (mg)
1 0 Drop on lips – 0 0.1 2
2 15 0.5 8 15 1 18
3 45 1.0 15 30 10 176
4 75 3.0 45 45 20 352
5 105 10 150 60 30 528
6 135 30 450 80 40 704
7 165 50 750 110 60 1,056
8 195 100 1,500 150 90 1,584
Total 195 2,925 250 4,400
aBased on a mean protein content of 1.5 g/100 ml; depending on brand, the protein content of infant formula is between 1.3 and 1.6 g/100 ml; of
follow-on formula, 1.7 and 1.9 g/100 ml
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[27, 28].
Risk assessment
Although it is impossible to predict reaction severity during
food challenges [29], some rules apply. Severe adverse
reactions are more likely with previous severe reactions,
with previous reactions on very low CMP doses, in older
children, in children suffering from asthma and after
prolonged exclusion of cow’s milk [6, 30, 31].
Severe reactions with CMP challenges, however, are
rare. During over 12 years of open challenges in Dutch
well-baby clinics [20], no severe adverse events have
been reported to the supervising committee (K.I. van
Drongelen, Netherlands Nutrition Centre, personal com-
munication) [20]. With the DBPCFC protocol presented
here, over 500 challenges have been performed without
any severe adverse events. Hence, CMP challenges can be
safely performed in general practices, provided basic
safety precautions are met. High-risk challenges should
be performed in the hospital.
Cow’s milk reintroduction
When CMA is refuted, standard formula and dairy products
can safely be reintroduced in the diet of the child or the
breast-feeding mother. Sometimes the child’s illness has put
so much strain on the parents that the help of a dietician is
required to complete the transition to a normal diet. When,
nevertheless, adverse reactions develop after reintroduction,
this may be due to the natural course of the underlying
condition (eczema), but often expresses the preset convic-
tion of the parents that notwithstanding the test outcome,
their child is suffering from CMA. These signs or
symptoms are likely to disappear when the introduction is
continued.
Therapy
Elimination of CMP from the diet is at present the only
proven therapy.
Breast-fed infants Breast-feeding mothers need to elimi-
nate all dairy products from their diets. There is
controversy about other measures; as the child is at
increased risk of other food allergies, it could be wise for
her to eliminate allergens such as soy, egg and beef as
well [8]. This increases the burden for the mother,
however, and may provoke the failure of breast-feeding.
A practical approach would be to start with CMP
elimination and to eliminate other products only when
the child remains symptomatic.
Bottle-fed infants Formula is replaced by hypoallergenic
formula based on extensively hydrolysed CMP [32]. There
is limited experience with hydrolysates from other sources,
such as soy and collagen. The use of soy formula in infants
<6 months is discouraged [23, 33]. The only formulas
suitable for treatment are those that meet the criterium of
being tolerated (with 95% confidence interval) by at least
90% of patients with proven CMA [34]. The protein source
may be based on extensively hydrolysed whey protein
(eHW) or casein (eHC). Children that do not tolerate eHW
may be able to tolerate eHC, and the other way round;
despite differences in production and in vitro test results,
there is no proven difference in clinical efficacy between
both groups of formulas.
Some subgroups, including children with non-IgE-
mediated gastrointestinal CMA and severe atopic eczema,
may show better results with amino-acid-based formulas as
opposed to eHC or eHW [35]. Amino-acid-based formulas
Symptoms 
following challenge 
Challenge outcome 
positive 
Challenge outcome 
negative 
Different from 
history
No 
Symptoms of 
allergic nature 
Yes 
Similar to 
history 
Yes  No 
Fig. 1 Algorithm for the evaluation of the DBPCFC tests. The
diagnosis of CMA can be derived from the combined results of both
tests, placebo and verum (see Table 3). Adapted from 26
Table 3 Interpretation of DBPCFCs
Verum challenge Placebo challenge Test outcome
Positive Negative Positive
Strongly positive Positive Positive
Positive Positive Negative
Negative Negative Negative
Positive Strongly positive Negative
Adapted from 26.
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extensively hydrolysed formulas.
Solids There is no need to postpone the introduction of
solid foods or to follow a detailed introduction schedule.
Most children can tolerate other (non-dairy) foods when
introduced after the age of 4 months. In highly allergic
children, solids are best introduced stepwise: only one or
two new foods every 3 days. Because many parents are
anxious to proceed with solid food introduction, dietary
advice and guidance may be necessary.
Counselling The diagnosis of CMA has a great impact on
the family. Proper education of parents and caretakers is
essential. They need not only to learn avoidance strategies,
such as reading food labels and avoiding high-risk
situations, but also to recognise early signs and symptoms
and to treat acute reactions. Antihistamines are prescribed
for mild dermal conditions but will not suffice for severe
systemic reactions. Anaphylactic reactions to CMP are rare;
the parents of children with a history of anaphylaxis should
be provided an epinephrine auto-injector and a written
individualised treatment plan [36].
Tolerance induction
In the past decade, there is increasing interest in specific
oral or sublingual immune therapy as a treatment option for
CMA in older children [37, 38]. Immune therapy may lead
to an increased tolerance threshold for CMP with persisting
CMA [39] and may even induce permanent tolerance to
CMP [37]. More research needs to be done before immune
therapy can be offered as a competing therapeutic option.
Prognosis
CMA usually is a temporary condition. It is suggested that
by the age of 3 years, 85% of children have regained
tolerance to CMP [40]. More recent studies, however, are
less optimistic; persisting IgE-mediated CMA is reported to
persist up to the age of 8 years in 15% [41] to even 58% of
children [42]. It is advisable to repeat challenges at regular
intervals in order to keep the child on an elimination diet no
longer than strictly necessary. There is no reason for
DBPCFCs unless the diagnosis never has been made
properly. Challenges can be scheduled at the ages of 12,
18 and 24 months and yearly thereafter.
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